JUBALYX Trademark

Trademark Overview


On Thursday, June 2, 2022, a trademark application was filed for JUBALYX with the United States Patent and Trademark Office. The USPTO has given the JUBALYX trademark a serial number of 97440272. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Thursday, November 21, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The JUBALYX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

General Information


Serial Number97440272
Word MarkJUBALYX
Filing DateThursday, June 2, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateThursday, November 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, June 10, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, June 6, 2022NEW APPLICATION ENTERED
Friday, June 10, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 28, 2023ASSIGNED TO EXAMINER
Friday, March 3, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, November 27, 2023SOU TEAS EXTENSION RECEIVED
Monday, November 27, 2023SOU EXTENSION 1 FILED
Monday, November 27, 2023SOU EXTENSION 1 GRANTED
Wednesday, November 29, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 31, 2024SOU TEAS EXTENSION RECEIVED
Friday, May 31, 2024SOU EXTENSION 2 GRANTED
Friday, May 31, 2024SOU EXTENSION 2 FILED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 21, 2024SOU TEAS EXTENSION RECEIVED
Thursday, November 21, 2024SOU EXTENSION 3 FILED
Thursday, November 21, 2024SOU EXTENSION 3 GRANTED
Friday, November 22, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED